Glenmark Pharma launches COPD treatment inhaler in UK

Drug firm Glenmark Pharma on Tuesday announced the launch of Tiotropium Bromide Dry Powder Inhaler, used in the treatment of chronic obstructive pulmonary disease (COPD), in the UK. Tiotropium DPI had a market size of USD 450 million in the EU in the 12 month period ending September 2020.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3gqDiQ2
via IFTTT